{"id":21726,"date":"2022-07-14T16:34:45","date_gmt":"2022-07-14T14:34:45","guid":{"rendered":"https:\/\/www.mannheimerswartling.se\/?p=21726"},"modified":"2023-03-30T13:14:54","modified_gmt":"2023-03-30T11:14:54","slug":"bioinvent-har-genomfort-en-riktad-nyemission","status":"publish","type":"post","link":"https:\/\/www.mannheimerswartling.se\/uppdrag\/bioinvent-har-genomfort-en-riktad-nyemission\/","title":{"rendered":"BioInvent har genomf\u00f6rt en riktad nyemission"},"content":{"rendered":"<p class=\"preamble\">BioInvent har genomf\u00f6rt en riktad nyemission om cirka SEK 300 miljonertill internationella och svenska institutionella investerare.<\/p>\n<p>BioInvent \u00e4r ett f\u00f6retag i klinisk fas som fokuserar p\u00e5 att utveckla nya, first-in-class immunmodulerande antikroppar f\u00f6r cancerbehandling. BioInvents aktier \u00e4r noterade p\u00e5 Nasdaq Stockholm (BINV).<\/p>\n<p>BioInvent r\u00e5dgavs av Mannheimer Swartling i transaktionen.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BioInvent har genomf\u00f6rt en riktad nyemission om cirka SEK 300 miljonertill internationella och svenska institutionella investerare. BioInvent \u00e4r ett f\u00f6retag i klinisk fas som fokuserar\u2026<\/p>\n","protected":false},"author":7,"featured_media":20282,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[3469],"tags":[],"class_list":["post-21726","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uppdrag","business-group-publik-ma-och-aktiemarknad"],"acf":[],"lang":"sv","translations":{"sv":21726,"en":21728},"pll_sync_post":[],"_links":{"self":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21726"}],"collection":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/comments?post=21726"}],"version-history":[{"count":2,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21726\/revisions"}],"predecessor-version":[{"id":24034,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/posts\/21726\/revisions\/24034"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media\/20282"}],"wp:attachment":[{"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/media?parent=21726"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/categories?post=21726"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.mannheimerswartling.se\/wp-json\/wp\/v2\/tags?post=21726"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}